[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"complete-digeorge-syndrome\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:complete-digeorge-syndrome":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":28,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":5},"100464610","congenital-athymia-patient-registry-100464610",false,"NCT05329935","Congenital Athymia Patient Registry","Congenital Athymia Patient Registry of RETHYMIC","Inclusion Criteria:\n\n* Pediatric patients diagnosed with Congenital Athymia:\n\n  * Who are scheduled for implantation with RETHYMIC within the next 30 days, or who were treated with RETHYMIC within the previous 60 days.\n  * Who have provided written informed consent directly, or written informed consent has been provided by the patient, the parent, or legal guardian.\n\nExclusion Criteria:\n\n* Written informed consent cannot be obtained.","ALL","0 Years","21 Years",{"count":20,"type":21},75,"ESTIMATED","OBSERVATIONAL","This Congenital Athymia Patient Registry is an observational exposure-based registry study. It uses a prospective cohort design to follow patients who have been treated with RETHYMIC.\n\nClinical studies conducted with investigational RETHYMIC showed that treatment can result in immune reconstitution and prolong life. This treatment-based registry is being conducted to learn more about the reconstitution process following treatment and the impact of treatment on longer-term survival and the occurrence of adverse events of special interest (AESI).",[25,26,27],"Complete DiGeorge Anomaly","Complete DiGeorge Syndrome","Congenital Athymia",[27],"RECRUITING","2025-08-14",{"date":32,"type":33},"2025-08-19","ACTUAL",{"date":35,"type":33},"2022-05-25",{"date":37,"type":21},"2026-04",{"name":39,"class":40},"Sumitomo Pharma Switzerland GmbH","INDUSTRY"]